OBJECTIVE To study the AmpC ?-lactamases form clinical isolates of Escherichia coli and Klebsiella pneumoniae in our hospital.METHODS Using confirmatory test recommended by the NCCLS to detect ESBLs produced by 369 strains E.coli and K.pneumoniae,adopting three-dimensional test was performed and three-dimensional depression test and AmpC ?-lactamases inducing test to detect the phenotype of screening strains producing AmpC ?-lactamases.RESULTS Among 73 strains whose phenotypes doubted of production of AmpC ?-lactamases 34 were AmpC ?-lactamases producing strains,of which 24 strains were E.coli and 10 strains were K.pneumoniae.Five E.coli strains and 2 K.pneumoniae strains produced ESBLs and AmpC ?-lactamases.At AmpC ?-lactamases inducing test,2 K.pneumoniae strains produced AmpC ?-lactamases.CONCLUSIONS AmpC ?-lactamases are the another most important resistance mechanisms of E.coli and K.pneumoniae,much attention should be paid to their detections and surveillance,it will direct the clinics to use antibiotics reasonably,relieve the selective pressure of bacteria resistance and avoid the nosocomial infection.

and 98.6% (436/442), respectively. Conclusion The ELISA based on fusion viral capsid proteins is sensitive, specific and accurate method for determining antibodies to VCA of EBV for both clinical diagnosis and epidemiology studies.

Objective To explore the clinical efficacy of second-line treatment with Zebutinib for mantle cell lymphoma.Methods Totally 80 patients with mantle cell lymphoma admitted to Ganzhou Cancer Hospital from October 2020 to December 2021 were divided into observation group and control group by lottery method,40 cases in each group.The control group received first-line treatment combined Bendamustine for mantle cell lymphoma,while the observation group received second-line treatment combined with Zebutinib on the basis of first-line treatment.The patients were followed up for 2 years.The clinical efficacy,tumor marker levels,immune function,survival cycle and treatment safety of two groups were evaluated and compared.Results The objective remission rate and disease control rate of observation group were higher than those of control group(P＜0.05).After treatment,the levels of lactate dehydrogenase,β2-microglobulin and carcinoembryonic antigen of observation group were lower than those of control group(P＜0.05).After treatment,the immune function indicators of observation group was better than that of control group(P＜0.05).The progression free survival and overall survival of observation group were higher than those of control group(P＜0.05).Conclusion Zebutinib second-line treatment for mantle cell lymphoma has a good effect,can reduce tumor marker levels,improve patients immune function,prolong patients survival cycle,and has good treatment safety.